Literature DB >> 16890450

Inverted rhythm of melatonin secretion in Smith-Magenis syndrome: from symptoms to treatment.

Hélène De Leersnyder1.   

Abstract

Smith-Magenis syndrome (SMS) is a mental retardation syndrome with distinctive behavioral characteristics, dysmorphic features and congenital anomalies ascribed to an interstitial deletion of chromosome 17p11.2. Severe sleep disturbances and maladaptative daytime behavior have been linked to an abnormal circadian secretion pattern of melatonin, with a diurnal instead of nocturnal secretion of this hormone. SMS provides a demonstration of a biological basis for sleep disorder in a genetic disease. Considering that clock genes mediate the generation of the circadian rhythm, haploinsufficiency for a circadian system gene, mapping to chromosome 17p11.2 might cause the inversion of the melatonin circadian rhythm in SMS. The disorder of circadian timing in SMS might also affect the entrainment pathway (retinohypothalamic tract), pacemaker functions (suprachiasmatic nucleus) or synthesis and release of melatonin by the pineal gland. Elucidating pathophysiological mechanisms of behavioral phenotypes in genetic disease can provide an original therapeutic approach in SMS: blockade of endogenous melatonin production during the day combined with exogenous melatonin administration in the evening.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16890450     DOI: 10.1016/j.tem.2006.07.007

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  18 in total

Review 1.  Sleep as a translationally-relevant endpoint in studies of autism spectrum disorder (ASD).

Authors:  Galen Missig; Christopher J McDougle; William A Carlezon
Journal:  Neuropsychopharmacology       Date:  2019-05-06       Impact factor: 7.853

2.  Abnormal circadian rhythm of melatonin in Smith-Magenis syndrome patients with RAI1 point mutations.

Authors:  Philip M Boone; Russel J Reiter; Daniel G Glaze; Dun-Xian Tan; James R Lupski; Lorraine Potocki
Journal:  Am J Med Genet A       Date:  2011-07-07       Impact factor: 2.802

Review 3.  Neurodevelopmental Disorders Associated with Abnormal Gene Dosage: Smith-Magenis and Potocki-Lupski Syndromes.

Authors:  Juanita Neira-Fresneda; Lorraine Potocki
Journal:  J Pediatr Genet       Date:  2015-09-28

4.  Aberrant Proteostasis of BMAL1 Underlies Circadian Abnormalities in a Paradigmatic mTOR-opathy.

Authors:  Jonathan O Lipton; Lara M Boyle; Elizabeth D Yuan; Kevin J Hochstrasser; Fortunate F Chifamba; Ashwin Nathan; Peter T Tsai; Fred Davis; Mustafa Sahin
Journal:  Cell Rep       Date:  2017-07-25       Impact factor: 9.423

Review 5.  Role of the melatonin system in the control of sleep: therapeutic implications.

Authors:  Seithikurippu R Pandi-Perumal; Venkatramanujan Srinivasan; D Warren Spence; Daniel P Cardinali
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

6.  Smith-Magenis syndrome results in disruption of CLOCK gene transcription and reveals an integral role for RAI1 in the maintenance of circadian rhythmicity.

Authors:  Stephen R Williams; Deborah Zies; Sureni V Mullegama; Michael S Grotewiel; Sarah H Elsea
Journal:  Am J Hum Genet       Date:  2012-05-10       Impact factor: 11.025

7.  Pineal gland expression of the transcription factor Egr-1 is restricted to a population of glia that are distinct from nestin-immunoreactive cells.

Authors:  Pui-Sin Man; David A Carter
Journal:  J Mol Histol       Date:  2007-08-02       Impact factor: 2.611

Review 8.  Neurodevelopmental Disorders Commonly Presenting with Sleep Disturbances.

Authors:  Althea Robinson Shelton; Beth Malow
Journal:  Neurotherapeutics       Date:  2021-01-05       Impact factor: 7.620

9.  Phenotypic consequences of copy number variation: insights from Smith-Magenis and Potocki-Lupski syndrome mouse models.

Authors:  Guénola Ricard; Jessica Molina; Jacqueline Chrast; Wenli Gu; Nele Gheldof; Sylvain Pradervand; Frédéric Schütz; Juan I Young; James R Lupski; Alexandre Reymond; Katherina Walz
Journal:  PLoS Biol       Date:  2010-11-23       Impact factor: 8.029

Review 10.  Neurobiology, pathophysiology, and treatment of melatonin deficiency and dysfunction.

Authors:  Rüdiger Hardeland
Journal:  ScientificWorldJournal       Date:  2012-05-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.